BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 33771891)

  • 1. High-dimensional analysis of the adenosine pathway in high-grade serous ovarian cancer.
    Bareche Y; Pommey S; Carneiro M; Buisseret L; Cousineau I; Thebault P; Chrobak P; Communal L; Allard D; Robson SC; Mes-Masson AM; Provencher D; Lapointe R; Stagg J
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33771891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD73 is associated with poor prognosis in high-grade serous ovarian cancer.
    Turcotte M; Spring K; Pommey S; Chouinard G; Cousineau I; George J; Chen GM; Gendoo DM; Haibe-Kains B; Karn T; Rahimi K; Le Page C; Provencher D; Mes-Masson AM; Stagg J
    Cancer Res; 2015 Nov; 75(21):4494-503. PubMed ID: 26363007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adenosine and the adenosine A2A receptor agonist, CGS21680, upregulate CD39 and CD73 expression through E2F-1 and CREB in regulatory T cells isolated from septic mice.
    Bao R; Shui X; Hou J; Li J; Deng X; Zhu X; Yang T
    Int J Mol Med; 2016 Sep; 38(3):969-75. PubMed ID: 27430240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of the CD39/CD73 Purinergic Pathway in Modulating Arterial Thrombosis in Mice.
    Covarrubias R; Chepurko E; Reynolds A; Huttinger ZM; Huttinger R; Stanfill K; Wheeler DG; Novitskaya T; Robson SC; Dwyer KM; Cowan PJ; Gumina RJ
    Arterioscler Thromb Vasc Biol; 2016 Sep; 36(9):1809-20. PubMed ID: 27417582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity.
    Häusler SF; Montalbán del Barrio I; Strohschein J; Chandran PA; Engel JB; Hönig A; Ossadnik M; Horn E; Fischer B; Krockenberger M; Heuer S; Seida AA; Junker M; Kneitz H; Kloor D; Klotz KN; Dietl J; Wischhusen J
    Cancer Immunol Immunother; 2011 Oct; 60(10):1405-18. PubMed ID: 21638125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies.
    Perrot I; Michaud HA; Giraudon-Paoli M; Augier S; Docquier A; Gros L; Courtois R; Déjou C; Jecko D; Becquart O; Rispaud-Blanc H; Gauthier L; Rossi B; Chanteux S; Gourdin N; Amigues B; Roussel A; Bensussan A; Eliaou JF; Bastid J; Romagné F; Morel Y; Narni-Mancinelli E; Vivier E; Paturel C; Bonnefoy N
    Cell Rep; 2019 May; 27(8):2411-2425.e9. PubMed ID: 31116985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The adenosine generating enzymes CD39/CD73 control microglial processes ramification in the mouse brain.
    Matyash M; Zabiegalov O; Wendt S; Matyash V; Kettenmann H
    PLoS One; 2017; 12(4):e0175012. PubMed ID: 28376099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD73 controls ocular adenosine levels and protects retina from light-induced phototoxicity.
    Losenkova K; Takeda A; Ragauskas S; Cerrada-Gimenez M; Vähätupa M; Kaja S; Paul ML; Schmies CC; Rolshoven G; Müller CE; Sandholm J; Jalkanen S; Kalesnykas G; Yegutkin GG
    Cell Mol Life Sci; 2022 Feb; 79(3):152. PubMed ID: 35212809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade.
    Yang R; Elsaadi S; Misund K; Abdollahi P; Vandsemb EN; Moen SH; Kusnierczyk A; Slupphaug G; Standal T; Waage A; Slørdahl TS; Rø TB; Rustad E; Sundan A; Hay C; Cooper Z; Schuller AG; Woessner R; Borodovsky A; Menu E; Børset M; Sponaas AM
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32409420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxidized low-density lipoproteins enhance expression and activity of CD39 and CD73 in the human aortic valve endothelium.
    Kaniewska-Bednarczuk E; Mielcarek M; Chester AH; Slominska EM; Yacoub MH; Smolenski RT
    Nucleosides Nucleotides Nucleic Acids; 2016 Dec; 35(10-12):713-719. PubMed ID: 27906627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ectonucleotidase CD73 and CD39 expression in non-small cell lung cancer relates to hypoxia and immunosuppressive pathways.
    Giatromanolaki A; Kouroupi M; Pouliliou S; Mitrakas A; Hasan F; Pappa A; Koukourakis MI
    Life Sci; 2020 Oct; 259():118389. PubMed ID: 32898522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adenosine and inflammation: CD39 and CD73 are critical mediators in LPS-induced PMN trafficking into the lungs.
    Reutershan J; Vollmer I; Stark S; Wagner R; Ngamsri KC; Eltzschig HK
    FASEB J; 2009 Feb; 23(2):473-82. PubMed ID: 18838482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD39-mediated ATP-adenosine signalling promotes hepatic stellate cell activation and alcoholic liver disease.
    Shuai C; Xia GQ; Yuan F; Wang S; Lv XW
    Eur J Pharmacol; 2021 Aug; 905():174198. PubMed ID: 34033815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extracellular generation of adenosine by the ectonucleotidases CD39 and CD73 promotes dermal fibrosis.
    Fernández P; Perez-Aso M; Smith G; Wilder T; Trzaska S; Chiriboga L; Franks A; Robson SC; Cronstein BN; Chan ESL
    Am J Pathol; 2013 Dec; 183(6):1740-1746. PubMed ID: 24266925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autocrine Adenosine Regulates Tumor Polyfunctional CD73
    Gourdin N; Bossennec M; Rodriguez C; Vigano S; Machon C; Jandus C; Bauché D; Faget J; Durand I; Chopin N; Tredan O; Marie JC; Dubois B; Guitton J; Romero P; Caux C; Ménétrier-Caux C
    Cancer Res; 2018 Jul; 78(13):3604-3618. PubMed ID: 29559470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD39 - A bright target for cancer immunotherapy.
    Guo S; Han F; Zhu W
    Biomed Pharmacother; 2022 Jul; 151():113066. PubMed ID: 35550530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of the CD39-CD73-adenosine pathway in liver disease.
    Wang S; Gao S; Zhou D; Qian X; Luan J; Lv X
    J Cell Physiol; 2021 Feb; 236(2):851-862. PubMed ID: 32648591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resident cardiac immune cells and expression of the ectonucleotidase enzymes CD39 and CD73 after ischemic injury.
    Bönner F; Borg N; Burghoff S; Schrader J
    PLoS One; 2012; 7(4):e34730. PubMed ID: 22514659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High expression of ecto-nucleotidases CD39 and CD73 in human endometrial tumors.
    Aliagas E; Vidal A; Texidó L; Ponce J; Condom E; Martín-Satué M
    Mediators Inflamm; 2014; 2014():509027. PubMed ID: 24707115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD39 and CD73 in the aortic valve-biochemical and immunohistochemical analysis in valve cell populations and its changes in valve mineralization.
    Kaniewska-Bednarczuk E; Kutryb-Zajac B; Sarathchandra P; Pelikant-Malecka I; Sielicka A; Piotrowska I; Slominska EM; Chester AH; Yacoub MH; Smolenski RT
    Cardiovasc Pathol; 2018; 36():53-63. PubMed ID: 30056298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.